Cargando…

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

INTRODUCTION: Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishøy, Pelle L, Knop, Filip K, Broberg, Brian V, Baandrup, Lone, Fagerlund, Birgitte, Jørgensen, Niklas R, Andersen, Ulrik B, Rostrup, Egill, Glenthøj, Birte Y, Ebdrup, Bjørn H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Mental Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902332/ https://www.ncbi.nlm.nih.gov/pubmed/24401727 http://dx.doi.org/10.1136/bmjopen-2013-004158

Ejemplares similares

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
por: Ebdrup, Bjørn H, et al.
Publicado: (2012)

Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial
por: Ishøy, Pelle L., et al.
Publicado: (2016)

F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
por: Jessen, Kasper, et al.
Publicado: (2018)

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
por: Eriksson, Robert, et al.
Publicado: (2019)

Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia
por: Anhøj, Simon, et al.
Publicado: (2018)

Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients
por: Ebdrup, Bjørn H., et al.
Publicado: (2019)

Frontal D(2/3) Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology
por: Nørbak-Emig, Henrik, et al.
Publicado: (2016)

M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAïVE SCHIZOPHRENIA PATIENTS
por: Nielsen, Mette, et al.
Publicado: (2020)

The impact of schizophrenia and intelligence on the relationship between age and brain volume
por: Jensen, Maria H., et al.
Publicado: (2018)

O3.3. REWARD PROCESSING AS A VULNERABILITY INDICATOR FOR PSYCHOSIS: RESULTS FROM A TWIN STUDY
por: Nielsen, Mette, et al.
Publicado: (2018)

Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naïve patients with psychosis
por: Bojesen, Kirsten Borup, et al.
Publicado: (2023)

Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers
por: Bojesen, Kirsten Borup, et al.
Publicado: (2018)

M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT
por: Bojesen, Kirsten, et al.
Publicado: (2020)

F16. GLUTAMATE AND GABA LEVELS IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS ARE ASSOCIATED WITH TREATMENT OUTCOME AFTER 1.5 AND 6 MONTHS
por: Bojesen, Kirsten, et al.
Publicado: (2018)

Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis
por: Bojesen, Kirsten B., et al.
Publicado: (2020)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol
por: Baandrup, Lone, et al.
Publicado: (2011)

Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis
por: Bojesen, Kirsten Borup, et al.
Publicado: (2021)

Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol
por: Baltzersen, Olga B., et al.
Publicado: (2020)

T16. GLUTAMATERGIC CHANGES IN UHR
por: Wenneberg, Christina, et al.
Publicado: (2018)

O4.2. HERITABILITY AND CORRELATION TO SCHIZOPHRENIA SPECTRUM DISORDER OF GLUTAMATE AND OTHER NEUROMETABOLITE LEVELS IN ANTERIOR CINGULATE AND LEFT THALAMUS: A REGISTER BASED MAGNETIC RESONANCE TWIN STUDY
por: Legind, Christian, et al.
Publicado: (2018)

Reward Processing as an Indicator of Vulnerability or Compensatory Resilience in Psychoses? Results From a Twin Study
por: Nielsen, Mette Ødegaard, et al.
Publicado: (2022)

Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice
por: Gundersen, Kristina Ballestad, et al.
Publicado: (2023)

S158. REWARD ALTERATIONS IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE-PSYCHOSIS PATIENTS BEFORE AND AFTER TREATMENT WITH A PARTIAL DOPAMINE AGONIST
por: Tangmose, Karen, et al.
Publicado: (2018)

Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial
por: Rasmussen, Jesper Østrup, et al.
Publicado: (2021)

S150. DOPAMINE SYNTHESIS CAPACITY IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOTIC PATIENTS
por: Sigvard, Anne, et al.
Publicado: (2018)

A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data
por: Ambrosen, Karen S., et al.
Publicado: (2020)

Supplementary data for a focused review and meta-analysis of (1)H-MRS studies on cerebral glutamate and GABA levels in high-risk of psychosis states
por: Wenneberg, Christina, et al.
Publicado: (2019)

S12. A MACHINE LEARNING FRAMEWORK FOR ROBUST AND RELIABLE PREDICTION OF SHORT- AND LONG-TERM CLINICAL RESPONSE IN INITIALLY ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BASED ON MULTIMODAL NEUROPSYCHIATRIC DATA
por: Ambrosen, Karen S, et al.
Publicado: (2020)

Brain Connectivity Studies in Schizophrenia: Unravelling the Effects of Antipsychotics
por: Nejad, Ayna B, et al.
Publicado: (2012)

Dopamine Synthesis Capacity and GABA and Glutamate Levels Separate Antipsychotic-Naïve Patients With First-Episode Psychosis From Healthy Control Subjects in a Multimodal Prediction Model
por: Sigvard, Anne K., et al.
Publicado: (2022)

Striatal Volume Increase After Six Weeks of Selective Dopamine D(2/3) Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients
por: Andersen, Helle G., et al.
Publicado: (2020)

Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis
por: Myken, Anders N, et al.
Publicado: (2022)

Value of gym-based group exercise versus usual care for young adults receiving antipsychotic medication: study protocol for the multicenter randomized controlled Vega trial
por: Rafn, Bolette Skjødt, et al.
Publicado: (2023)

Concurrent functional magnetic resonance imaging and electroencephalography assessment of sensory gating in schizophrenia
por: Bak, Nikolaj, et al.
Publicado: (2013)

Use of second-generation antipsychotics in autism spectrum disorder: a systematic review and meta-analysis protocol
por: Lopes, Luis Phillipe Nagem, et al.
Publicado: (2023)

A nation-wide twin study of social cognition in schizophrenia spectrum disorders
por: Lemvigh, Cecilie K., et al.
Publicado: (2022)

Effect of specialised versus generalised outpatient treatment for bipolar disorder: the CAG Bipolar trial - study protocol for a randomised controlled trial
por: Kessing, Lars Vedel, et al.
Publicado: (2021)

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)
por: Sass, Marie Reeberg, et al.
Publicado: (2023)

O9.5. NORMALIZATION OF DISTURBANCES IN PREDICTION ERROR IS RELATED TO TREATMENT RESPONSE AND RELATED TO THALAMIC GLUTAMATE LEVELS IN NON-RESPONDERS
por: Tangmose, Karen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_82rgh0qb6p4cg5a3vkill8689k